Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow
Y Sadzuka1, Y Egawa, T Sugiyama
1School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan. sadzuka@u-shizuoka-ken.ac.jp.
Abstract:
The effects of 1-methyl-3-propyl-7-butylxanthine (MPBX), a xanthine derivative, on idarubicin (IDA)-induced antitumor activity against P388 leukemia cells (P388) and bone marrow suppression were examined. In P388 tumor-bearing mice, the combination of MPBX with IDA increased the antitumor activity of IDA. The IDA concentration in the tumors in the MPBX combination group increased by 2.0-fold compared to the level in the IDA-alone group. On the other hand, as regards IDA-induced bone marrow suppression, the combination of MPBX with IDA reduced the decrease in the bone marrow cell number by 30% compared to that in the IDA-alone group. In addition, the IDA concentration in the bone marrow cells was decreased by the combination of MPBX with IDA. An in vitro experiment showed that MPBX facilitated IDA influx and suppressed IDA efflux in P388 cells. In conclusion, the combination of MPBX with IDA increased the antitumor activity and decreased the bone marrow suppression. Therefore, we expect that the combination of MPBX with IDA will be useful for leukemia chemotherapy.
Insights
Combining 1-methyl-3-propyl-7-butylxanthine (MPBX) with idarubicin (IDA) enhances antitumor effects against leukemia cells. This combination also reduces bone marrow suppression, showing potential for improved leukemia chemotherapy.
Area of Science:
- Pharmacology
- Cancer Research
- Hematology
Background:
- Idarubicin (IDA) is a chemotherapy drug used against leukemia.
- Bone marrow suppression is a significant side effect of IDA treatment.
- 1-methyl-3-propyl-7-butylxanthine (MPBX) is a xanthine derivative with potential modulatory effects.
Purpose of the Study:
- To investigate the combined effects of MPBX and IDA on antitumor activity against P388 leukemia.
- To evaluate the impact of MPBX and IDA combination on IDA-induced bone marrow suppression.
Main Methods:
- In vivo studies using P388 tumor-bearing mice.
- In vitro experiments assessing drug transport in P388 cells.
- Quantification of IDA concentration in tumor and bone marrow tissues.
Main Results:
- MPBX significantly increased IDA's antitumor activity in P388 leukemia models.
- The combination therapy led to a 2.0-fold increase in tumor IDA concentration.
- MPBX reduced bone marrow cell count decrease by 30% and lowered bone marrow IDA concentration.
Conclusions:
- MPBX enhances IDA's efficacy and mitigates its toxicity.
- MPBX facilitates IDA uptake and reduces its efflux in leukemia cells.
- The MPBX-IDA combination shows promise for more effective and safer leukemia chemotherapy.
